Phibro Animal Health Corporation · NASDAQ:PAHC
Phibro Animal Health — Q2 FY2018 Earnings Presentation
12 slides from Phibro Animal Health's earnings presentation, Feb 6, 2018
Slide 1: Phibro Animal Health Corporation Second Quarter Webcast and Conference Call
Phibro Animal Health Corporation Second Quarter - December 2017 U.S. toll-free +1-877-853-5634 Webcast and Conference Call International toll +1-315-625-6893 February 6, 2018 Conference ID: 69672295 February 6, 2018 Webcast and Conference Call
Slide 2: Cautionary Statements
Cautionary Statements Forward-Looking Statements This communication contains forward-looking statements that are subject to risks and uncertainties. All statements other than statements of historical or current fact included in this report are forward-looking statements. Forward-looking statements d
Slide 3: Opening Remarks and Financial Review
Opening Remarks and Financial Review Jack Bendheim Chairman, President, Chief Executive Officer Richard Johnson Chief Financial Officer 3 February 6, 2018 Webcast and Conference Call
Slide 4: GAAP and Non-GAAP Financial Information
GAAP and Non-GAAP Financial Information Reported results are presented in accordance with GAAP Adjusted results are GAAP results adjusted to exclude: - Acquisition-related items, including intangible amortization, cost of goods sold, accrued compensation costs, transaction costs and accrued interest
Slide 5: Highlights Q2 – December 2017
Highlights Q2 – December 2017 Sales growth across all segments For the three months ended Net income and diluted EPS declined 2017 2016 Change December 31 Higher income tax expense due to one time charges (in millions, except per share amounts and percentages) from the income tax legislation and oth
Slide 6: Selected Line Items
Selected Line Items Q2 – December 2017 For the three months ended December 31 2017 2016 Change Adjusted SG&A increased due to investments in (in millions, except per share amounts and percentages) Animal Health product and organization Net sales $ 205.9 $ 191.6 $ 14.3 7% Adjusted gross profit 69.6 6
Slide 7: Animal Health
Animal Health Q2 – December 2017 Sales - Nutritional specialties: Volume growth in U.S. poultry and Animal Health dairy industries and penetration into various international countries For the three months ended December 31 2017 2016 Change - Vaccines: Volume growth in international markets; domestic
Slide 8: Other Segments
Other Segments Q2 – December 2017 For the three months ended 2017 2016 Change December 31 (in millions, except percentages) Mineral Nutrition Mineral Nutrition Net sales $ 59.6 $ 56.7 $ 2.9 5% – Sales growth on favorable product mix and increased commodity pricing Adjusted EBITDA $ 5.6 $ 4.7 $ 0.9 1
Slide 9: Capitalization and Capital Allocation
Capitalization and Capital Allocation December 31, 2017 2.6x leverage ratio at December 31, 2017 - $318 million total debt - $122 million LTM Adjusted EBITDA $67 million cash and short-term investments on hand at December 31, 2017 $28 million source of cash before financing for the December 2017 qua
Slide 10: Guidance
Guidance We are updating our annual guidance For the year ending June 30 2018 2017 Change from 2017 Change from Previous Guidance (in millions, except per share amounts and percentages) Net sales - Animal Health segment $ 520 - $ 535 $ 498 $ 22 - $ 37 4% - 7% $ 20 - $ 20 Net sales $ 800 - $ 825 $ 76
Slide 11: Q & A Session
Q&A Session 11 February 6, 2018 Webcast and Conference Call
Slide 12: © 2018 Phibro Animal Health Corporation, Teaneck, NJ 07666 Phibro; Phibro logo design; Healthy
© 2018 Phibro Animal Health Corporation, Teaneck, NJ 07666 Phibro; Phibro logo design; Healthy Animals. Healthy Food. Healthy World.; AB20; Animate; Aviax; Cellerate Yeast Solutions; Gemstone; Lactrol; Magni-Phi; Mecadox; MJPRRS; Neo-Terra; Neo- Terramycin; Neo-TM; Nicarb; OmniGen-AF; PAQ-Gro; Stafa
Phibro Animal Health — Q2 FY2018 Earnings Presentation on 6ix